

Reference number(s)
1662-A

# SPECIALTY GUIDELINE MANAGEMENT

## Mitoxantrone

### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### A. FDA-Approved Indications

1. Acute nonlymphocytic leukemia (ANLL)  
Mitoxantrone in combination with other approved drug(s) is indicated in the initial therapy of ANLL in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias.
2. Multiple sclerosis  
Mitoxantrone is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (MS) (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone is not indicated in the treatment of patients with primary progressive MS.
3. Prostate cancer  
Mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.

##### B. Compendial Uses

1. Acute lymphoblastic leukemia
2. Breast cancer<sup>2</sup>
3. Hodgkin lymphoma<sup>3</sup>
4. Liver carcinoma<sup>2</sup>
5. Malignant lymphoma, indolent<sup>2</sup>
6. Non-Hodgkin's lymphoma with following subtypes<sup>3</sup>
  - a. AIDS-related B-cell lymphoma
  - b. Diffuse large B-cell lymphoma
  - c. Follicular lymphoma
  - d. Histologic transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma
  - e. Mantle cell lymphoma
  - f. T-cell prolymphocytic leukemia
  - g. Post-transplant proliferative disorders
7. Ovarian cancer<sup>2</sup>

All other indications are considered experimental/investigational and not medically necessary.

#### II. CRITERIA FOR INITIAL APPROVAL

##### A. Acute lymphoblastic leukemia (ALL)

Mitoxantrone 1662-A SGM P2020

© 2020 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Reference number(s)
1662-A

Authorization of 6 months may be granted for treatment of ALL.

**B. Acute nonlymphocytic leukemia (ANLL)**

Authorization of 6 months may be granted for treatment of ANLL, including acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL).

**C. Multiple sclerosis**

Authorization of 1 dose (3 months) may be granted for treatment of multiple sclerosis.

**D. Prostate cancer**

Authorization of 6 months may be granted for treatment of prostate cancer.

**E. Breast cancer**

Authorization of 6 months may be granted for treatment of breast cancer.

**F. Hodgkin lymphoma**

Authorization of 6 months may be granted for treatment of Hodgkin lymphoma.

**G. Liver carcinoma<sup>2</sup>**

Authorization of 6 months may be granted for treatment of liver carcinoma.

**H. Non-Hodgkin's lymphoma (NHL)**

Authorization of 6 months may be granted for treatment of one of the following subtypes of NHL:

1. AIDS-related B-cell lymphoma
2. Diffuse large B-cell lymphoma
3. Follicular lymphoma
4. Histologic transformation of nodal marginal zone lymphoma to diffuse large B-cell lymphoma
5. Mantle cell lymphoma
6. T-cell prolymphocytic leukemia
7. Post-transplant proliferative disorders

**I. Ovarian cancer**

Authorization of 6 months may be granted for treatment of ovarian cancer.

**J. Malignant lymphoma, indolent**

Authorization of 6 months may be granted for treatment of malignant indolent lymphoma.

**III. CONTINUATION OF THERAPY**

**A. Multiple Sclerosis**

Authorization of 3 months may be granted for continued treatment in members requesting reauthorization for multiple sclerosis (MS) who experienced a benefit from therapy (e.g., reduced neurologic disability, reduced frequency of clinical relapses).

**B. All Other Diagnoses (Excluding Multiple Sclerosis)**

Authorization of 6 months may be granted for continued treatment in members requesting reauthorization for all indications listed in Section II (excluding MS) when there is no evidence of unacceptable toxicity.

**IV. REFERENCES**

Reference number(s)
1662-A

1. Mitoxantrone [package insert]. Lake Forest, IL: Hospira, Inc.; May 2018.
2. IBM Micromedex® DRUGDEX® System (electronic version). IBM Watson Health, Greenwood Village, Colorado. Available at <https://www.micromedexsolutions.com>. Accessed February 25, 2020.
3. The NCCN Drugs & Biologics Compendium® © 2020 National Comprehensive Cancer Network, Inc. <https://www.nccn.org>. Accessed February 25, 2020.